Oral diseases · 2025
EGFR T790M Mutations in Conventional and Langerhans Cell-Rich Variants of CEOT: Unveiling Molecular Differences and Clinical Implications.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Wenyi, Xue Jiang, Sun Lisha, Sun Zhipeng
Аннотация
OBJECTIVES: We aimed to investigate the clinicopathologic and molecular characteristics of conventional and Langerhans cell-rich (LC-rich) variants of Calcifying Epithelial Odontogenic Tumor (CEOT).
METHODS: Fifteen patients, eight with conventional and seven with LC-rich variants, were analyzed using clinical data, radiographic features, and histopathologic assessments. A 560-gene cancer panel, utilizing Agilent probe hybrid capture technology, was employed for next-generation sequencing (NGS) to detect genetic mutations. The EGFR c.2369C>T (p.T790M) mutation was identified and further validated using droplet digital PCR (ddPCR).
RESULTS: Our findings revealed that conventional CEOT primarily occurred in the mandible, with 75% displaying the EGFR c.2369C>T (p.T790M) mutation. Conversely, the LC-rich variant was more prevalent in the maxilla, with 28.57% exhibiting the same mutation. Radiographic patterns showed distinct differences, with the LC-rich variant demonstrating more aggressive clinical behavior.
CONCLUSIONS: The identification of EGFR c.2369C>T (p.T790M) mutations in both variants underscores its significant role in CEOT pathogenesis and suggests potential implications for targeted therapies. This comprehensive analysis enhances our understanding of the molecular landscape of CEOT variants and highlights the necessity for tailored diagnostic and treatment strategies.
METHODS: Fifteen patients, eight with conventional and seven with LC-rich variants, were analyzed using clinical data, radiographic features, and histopathologic assessments. A 560-gene cancer panel, utilizing Agilent probe hybrid capture technology, was employed for next-generation sequencing (NGS) to detect genetic mutations. The EGFR c.2369C>T (p.T790M) mutation was identified and further validated using droplet digital PCR (ddPCR).
RESULTS: Our findings revealed that conventional CEOT primarily occurred in the mandible, with 75% displaying the EGFR c.2369C>T (p.T790M) mutation. Conversely, the LC-rich variant was more prevalent in the maxilla, with 28.57% exhibiting the same mutation. Radiographic patterns showed distinct differences, with the LC-rich variant demonstrating more aggressive clinical behavior.
CONCLUSIONS: The identification of EGFR c.2369C>T (p.T790M) mutations in both variants underscores its significant role in CEOT pathogenesis and suggests potential implications for targeted therapies. This comprehensive analysis enhances our understanding of the molecular landscape of CEOT variants and highlights the necessity for tailored diagnostic and treatment strategies.